Clinical Trials Logo

Mixed Lineage Acute Leukemia clinical trials

View clinical trials related to Mixed Lineage Acute Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05735184 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Start date: July 18, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

NCT ID: NCT04067336 Recruiting - Clinical trials for Acute Myeloid Leukemia

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Start date: September 12, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.

NCT ID: NCT04065399 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

AUGMENT-101
Start date: November 5, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

NCT ID: NCT02419755 Terminated - Clinical trials for Acute Myeloid Leukemia

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Start date: April 14, 2015
Phase: Phase 2
Study type: Interventional

This study will test the safety and effectiveness of adding bortezomib and vorinostat to other chemotherapy drugs commonly used to treat relapsed or refractory leukemia. Both drugs have been approved by the Food and Drug Administration (FDA) to treat other cancers in adults, but they have not yet been approved tor treatment younger patients with leukemia. PRIMARY OBJECTIVE - To estimate the overall response rate of patients with MLL rearranged (MLLr) hematologic malignancies receiving bortezomib and vorinostat in combination with a chemotherapy backbone. SECONDARY OBJECTIVES - Estimate event-free and overall-survival. - Describe toxicities experienced by participants during treatment. OTHER PRESPECIFIED OBJECTIVES - To identify all genomic lesions by comprehensive whole genome, exome and transcriptome sequencing on all patients. - To compare minimal residual disease (MRD) results by three modalities: flow cytometry, polymerase chain reaction (PCR) and deep sequencing.